# Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

> **NCT05442346** · NA · SUSPENDED · sponsor: **Bioray Laboratories** · enrollment: 5 (estimated)

## Conditions studied

- Thalassemia Major

## Interventions

- **BIOLOGICAL:** γ-globin reactivated autologous hematopoietic stem cells

## Key facts

- **NCT ID:** NCT05442346
- **Lead sponsor:** Bioray Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-12-25
- **Primary completion:** 2024-09-08
- **Final completion:** 2024-11-30
- **Target enrollment:** 5 (ESTIMATED)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442346, "Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05442346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*